You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Product menu

Augmentin: 40 years of patient experience and relentless innovation1,2

Our continuous research and robust manufacturing processes help us deliver a high quality antibiotic that promises reliable results.

Why Augmentin?

With presence in over 100 countries and accounting for over 190 million treatment courses in a year globally, Augmentin has built a legacy of clinical experience and trust. Augmentin is committed to Antibiotic stewardship and has been recognised by the prestigious AMR Benchmark report. 3,4,5

Confidence in every dose

Efficacy

Augmentin has proven efficacy in the elimination of infections caused by a wide spectrum of bacteria for treatment success.

 

EXPLORE

Guidelines

Major international guidelines recommend a combination of amoxicillin and clavulanic acid to treat a wide variety of bacterial infections

 

EXPLORE

Susceptibility

Comprehensive surveillance data show that key pathogens are susceptible to the combination of amoxicillin and clavulanic acid


EXPLORE

Sci-Flix

Enjoy bite-sized, scientific videos on topics of your interest to help you make and informed prescription choice.

Explore Sci-Flix Playlist

Day in Life of Moisture

Discover the perfect balance achieved in the manufacturing processes as key for producing a highly trusted antibiotic for more than 40 years.

Augmentin vs Antimicrobial Resistance

Discover how ongoing innovation in formulations and stringent quality controls of Augmentin ensure reliable results in the treatment of infections and address the growing antimicrobial resistance.

Make Every Prescription Count

See how the appropriate antibiotic prescription is the key to achieving the best results and tackling antimicrobial resistance in the community.

The Perfect Match

Explore how innovation, research, and stringent quality control make Augmentin one of the most prescribed antibiotics in the world.

EXPLORE SCI-FLIX PLAYLIST

packshot

Indications

  • Upper respiratory tract infections
  • Lower respiratory tract infections
  • Genito-urinary tract infections
  • Skin and soft tissue infections
  • Bone and joint infections
  • Dental infections e.g. severe dental abscess
  • Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.

Safety Information

  • Warnings and Precautions

    Hepatic impairment: Dose with caution. Monitor hepatic function at regular intervals. Administration: Administer at start of meal.
    Treatment with oral Augmentin should not exceed 14 days without review.

    CONTRA-INDICATIONS: Hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins & previous history of Augmentin associated jaundice/hepatic dysfunction.

    PRECAUTIONS: Fatal hypersensitivity reactions reported. Avoid in infectious mononucleosis. Prolonged use may result in overgrowth of non-susceptible organisms.
    Prolongation of bleeding time and prothrombin time. Use with caution in patients on anti-coagulation therapy. Reversible cholestatic jaundice reported rarely.
    Use with caution in patients with hepatic dysfunction. In patients with reduced urine output, crystalluria observed rarely.
    With high doses, advisable to maintain adequate fluid intake and urinary output in order to reduce possibility of crystalluria.
    In patients with renal impairment dosage should be adjusted as recommended.

    ABILITY TO DRIVE AND USE MACHINES: Adverse effects not observed.

  • Interactions

    Concomitant use of probenecid is not recommended. Concomitant use of allopurinol can increase likelihood of allergic skin reactions.
    May affect gut flora, leading to lower oestrogen reabsorption and reduced efficacy of oral contraceptives.

  • Pregnancy and Lactations

    Avoid in pregnancy, especially during the first trimester, unless considered essential by the physician.
    May be administered during lactation, keeping in mind the risk of sensitisation to infant.

  • Adverse Effects

    Mucocutaneous candidiasis, reversible leucopenia and thrombocytopenia, reversible agranulocytosis and haemolytic anaemia, angioneurotic oedema, anaphylaxis, serum sickness-like syndrome, hypersensitivity vasculitis, dizziness, headache, reversible hyperactivity and convulsions, diarrhoea, nausea, vomiting, indigestion, antibiotic-associated colitis, black hairy tongue, moderate rise in AST and/or ALT, hepatitis, cholestatic jaundice, skin rash, pruritus, urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative-dermatitis, acute generalised exanthemous pustulosis, interstitial nephritis, superficial tooth discolouration. Rarely death.

    OVERDOSAGE: Gastrointestinal symptoms and disturbance of fluid and electrolyte balances treated symptomatically. Haemodialysis if required.

 

 

Need help with this product?

Request a contact

Need help

Stay Informed

Prescribing Information

References

  1. European Medicines Agency. Scientific conclusions and grounds for amendment of the summaries of product characteristics, labelling and package leaflet presented by the EMEA. [Internet] 2008. [Cited 5 September 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/augmentin.
  2. White AR, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53(Suppl 1):i3–i20.
  3. IQVIA MAT. April 2021
  4. GSK Data on File;2019N415326_00;1-4 (1)
  5. Antimicrobial Resistance Benchmark 2021. [Internet] November 2021 [Cited 22 January 2024]. Available from: https://accesstomedicinefoundation.org/medialibrary/resources/61ee760d03810_Antimicrobial%20Resistance%20Benchmark%20report%202021.pdf.

Prepared by GSK. For adverse events reporting or product complaints contact GSK by email fv.aecaricam@gsk.com or phone : Jamaica +1(876) 630-2074.
GSK Offices, Oceania Business Plaza Torre 1000 floor 34. Panama, Republic of Panama, C.A. All rights reserved GSK. The complete prescribing information and/or reference are available upon request. Trade marks are owned by or licensed to the GSK group of companies. Material Exclusive for Healthcare Professionals.

Augmentin is a registered trademark of the GlaxoSmithKline group of companies.

PM-RCH-ACA-WCNT-230005 | Approval date: January 2024. Expiration date: January 2026.